Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial phase III controlled trial

A phase III 2 X 2 factorial trial of cisplatinum and bleomycin in 116 patients with recurrent or advanced squamous cell carcinoma of the head and neck is reported. Thirty percent of patients proved to be unfit for chemotherapy, and of those treated progression of tumour was the commonest "respo...

Full description

Saved in:
Bibliographic Details
Published in:Cancer chemotherapy and pharmacology 1985-01, Vol.15 (3), p.283-289
Main Authors: MORTON, R. P, RUGMAN, F, DORMAN, E. B, STONEY, P. J, WILSON, J. A, MCCORMICK, M, VEEVERS, A, STELL, P. M
Format: Article
Language:English
Subjects:
Aged
Antineoplastic agents
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Bleomycin - administration & dosage
Bleomycin - therapeutic use
Carcinoma, Squamous Cell - drug therapy
Chemotherapy
Cisplatin - administration & dosage
Cisplatin - therapeutic use
Clinical Trials as Topic
Female
Follow-Up Studies
Head and Neck Neoplasms - drug therapy
Humans
Male
Medical sciences
Middle Aged
Neoplasm Metastasis
Pharmacology. Drug treatments
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A phase III 2 X 2 factorial trial of cisplatinum and bleomycin in 116 patients with recurrent or advanced squamous cell carcinoma of the head and neck is reported. Thirty percent of patients proved to be unfit for chemotherapy, and of those treated progression of tumour was the commonest "response". However, 25% of patients achieved a partial or complete response, with no significant difference in response rates between the treated arms. The median number of courses received was 1 (range 0-6) and the commonest causes for discontinuation of treatment were renal toxicity and death. Bleomycin reduced survival, but not significantly so, whereas cisplatinum prolonged median survival significantly by 10 weeks. Significant predictors of survival, in addition to treatment by cisplatinum, were age, performance status, N status, number of courses and response of the tumor.
ISSN:0344-5704
1432-0843
DOI:10.1007/BF00263902